ARTICLE | Company News
Acadia Pharmaceuticals, The Michael J. Fox Foundation for Parkinson's Research neurology news
April 2, 2012 7:00 AM UTC
Acadia received a supplemental grant of $322,000 from the foundation to develop selective agonists of nuclear receptor subfamily 4 group A member 2 (NR4A2; NURR1) to treat Parkinson's disease. The gra...